Comparison

Leinco Technologies

Leinco Technologies

Leinco Technologies a biotechnology company, headquartered in St. Louis, Missouri, USA. With 30 years of experience, Leinco manufactures research products such as antibodies (monoclonal, polyclonal, recombinant), biologically active proteins, recombinant proteins, assays and more for life science, biopharmaceutical and diagnostic scientists.

Leinco has a range of around 4,000 products that have been cited in numerous publications. Great emphasis is placed on the quality and purity of their products to provide scientists with reproducible results.

Leinco's products are used in a wide range of cell, tissue and in vivo applications (e.g. spatial biology, flow cytometry, pre-clinical in vivo and in vitro studies).

Leinco has also established itself as a leading provider of custom R&D and manufacturing services, with a focus on monoclonal antibodies and recombinant proteins.

Leinco's in vivo antibodies

Antibodies can bind in a variety of ways, which has been exploited in in vivo diagnostics. Leincos in vivo antibodies serve the purpose of research and are applied in living animals or cells, for cell depletion, activation, neutralization or blocking and many more. Monoclonal antibodies are primarily used here.

Leinco has proprietary methods to produce its functional in vivo antibodies in outstanding quality and highest purity standards. Two quality standards of in vivo antibodies are maintained, In vivo GOLDTM and In vivo PLATINUMTM.

Both series offer monoclonal in vivo antibodies with cross-reactivity for mouse and human species, among others.

Difference between the In vivo GOLDTM and In vivo PLATINUMTM Mabs series

The differences between the functional in vivo antibody product series are characterized as follows:

In vivo GOLDTM Mabs

  • Purity > 95% by SDS-PAGE and ≥ 95% monomer by analytical SEC
  • Endotoxin ≤ 1.0 EU/mg
  • Contains no preservatives or carrier proteins
  • Sterile PBS pH 7.2 - no K or Ca
  • Applications include in vivo functional studies and can be used for WB, FC, IF or IHC
  • If pathogen testing and higher purity specifications are required, see our In vivo Platinum™ Mabs


Table 1- Product selection of the In vivo GOLDTM Mabs series

Name Application SKU Clone
Anti-Human CD20 – Purified In vivo GOLDTM Functional Grade CyTOF®, FC , WB C1652 2H7
Anti-Human CD4 (Clone OKT-4) – Purified In vivo GOLD™ Functional Grade CODEX®, ELISA, FC, ICC ,IF Staining, IHC FF, IHC FFPE, IP, N, WB C9200 OKT-4
Anti-Human IL-4 – Purified In vivo GOLD™ Functional Grade CyTOF®, IHC, N, WB I-1163 MP4-25D2
Anti-Human CD16 (Clone 3G8) – Purified In vivo GOLD™ Functional Grade B, CyTOF®, FC, IHC FF, IP C2858 3G8
Anti-Mouse CD3 – Purified In vivo GOLD™ Functional Grade CODEX®, Costim, FC, IHC FF C2443 17A2
Anti-Mouse CD4 (Clone GK1.5) – Purified In vivo GOLD™ Functional Grade B, Costim, CyTOF®, Depletion, FA, FC, IHC, IP C1333 GK1.5
Anti-Mouse CD120a (TNFR1) (Clone 55R-593) – Purified In vivo GOLD™ Functional Grade IP, WB T245 55R-593

In vivo PLATINUMTM Mabs

  • Purity > 95% by SDS-PAGE and ≥ 98% monomer by analytical SEC
  • Endotoxin ≤ 0.5 EU/mg
  • Very low levels of leached protein A
  • Contains no preservatives or carrier proteins
  • Sterile PBS Ph 7.2 - no K or Ca
  • Applications include in vivo functional studies and can be used for WB, FC, IF or IHC
  • Pathogen tested (IMPACT1) (see Table 3)


Table 2- Product Selection of the In vivo PLATINUMTM Mabs Series

Name Application SKU Clone
Anti-Human CD20 – Purified In vivo GOLD™ Functional Grade CyTOF®, FC , WB C1651 2H7
Anti-Human CD4 (Clone OKT-4) – Purified In vivo GOLD™ Functional Grade CODEX®, ELISA, FC, ICC ,IF Staining, IHC FF, IHC FFPE, IP, N, WB C9205 OKT-4
Anti-Human IL-4 – Purified In vivo GOLD™ Functional Grade FA C8105 BC8
Anti-Human CD16 (Clone 3G8) – Purified In vivo GOLD™ Functional Grade B, CyTOF®, FC, IHC FF, IP C6858 3G8
Anti-Mouse CD3 – Purified In vivo GOLD™ Functional Grade CODEX®, Costim, FC, IHC FF C6443 17A2
Anti-Mouse CD32/CD16 – Purified In vivo PLATINUM™ Functional Grade CODEX®, FC, IHC FF, IP, WB C681 2.4G2
Anti-Mouse CD120a (TNFR1) (Clone 55R-593) – Purified In vivo PLATINUM™ Functional Grade FC, IP, WB T945 55R-593
Anti-Mouse CD155 (PVR) – Purified In vivo PLATINUM™ Functional Grade FC C6020 4.24.1

The In vivo PLATINUMTM series offers even higher quality and purity than the In vivo GOLDTM series in some respects. For example, the monomers are even better purified at 3%, the endotoxin content is reduced and, in addition, the antibodies are purified from leached protein A and are pathogen-free in a controlled manner according to Idexx Impact 1.

Table 3 - IDEXX IMPACT I (PCR-based) mouse pathogen profile for purified in vivo PLATINUM™-grade antibodies.

Mycoplasma sp. Mouse adenovirus 1 (MAV1) Lactate dehydrogenase-elevating virus (LDEV)
Mycoplasma pulmonis Mouse adenovirus 2 (MAV2) Mouse kidney parvovirus (MKPV)
Sendai virus Murine norovirus (MNV) Hantaan Virus
Mouse hepatitis virus (MHV) Reovirus 3 (REO3) Mouse cytomegalovirus (mCMV)
Pneumonia virus of mice (PVM) Mouse rotavirus (EDIM) K virus
Minute virus of mice (MVM) Ectromelia virus Mouse thymic virus (MTV)
Mouse parvovirus (MPV) Polyomavirus Corynebacterium bovis
Theiler’s murine encephalomyelitis (TMEV) Lymphocytic choriomeningitis virus (LCMV) Corynebacterium sp.

In vivo cell-specific depletion as a scope for in vivo antibodies - T cells, B cells, NK cells and more

Leinco's in vivo monoclonal antibodies, against mouse cell-specific surface proteins and cytokines, can be used to perform cell-specific depletions in in vivo studies. Depletion refers to the removal of specific cell types from a mixture of cells. This can occur in vivo as well as in vitro, naturally e.g. by HIV or therapy-induced.

By binding antibodies against a specific epitope of a cell surface, the cell in question can be recognized and destroyed by the complement system and subsequently degraded by phagocytosis.

Depletion is a useful tool in therapeutic, immunotherapeutic and diagnostic research. By removing specific cell types using antibodies, conclusions can be drawn about their immunological function and understanding of immunological processes can be improved.

In vivo experiments show that T cell depletion using a combination of anti-CD4 (clone GK1.5) and anti-CD8 antibodies (clone 2.43 or 53-5.8) is efficient and has less deleterious effects on other blood cell populations than the use of CD3 depletion antibodies (such as clone 145-2C11 or 17A2).

For in vivo application, numerous products from Leinco are available in different quality formats.

Table 5- Product selection for in vivo depletion ranked by clone and cell type for depletion.

Cell Type Target Clone In vivo GOLDTM In vivo PLATINUMTM
T-Zellen CD3ε 145-2C11 C1758 C2280
B-Zellen B220 RA3-6B2 C383 C2844
CD8+ T Zellen CD8α 2.43 C380 C2837
CD4+ T Zellen CD4 GK1.5 C1333 C2838
NK Zellen NK 1.1 PK136 N123 N268
ILCs Thy1.2 (CD90.2) 30H12 C393 C430
Monozyten Ly6G (Gr-1) RB6-8C5 G100 G153
Makrophagen CSF1R (CD115) AFS98 C2169 C2268
Neutrophile Ly6G 1A8 L280 L305
Eosinophile IL-5 TRFK5 I-1060 I-1192

What is the significance of biosimilars?

A biosimilar is a successor product, for example of a biotechnologically produced protein, to formerly patented biotechnologically produced drugs. The products are larger, more complex molecules. Their dosage form usually corresponds to an injection solution.

Biosimilars are drugs with defined molecular structures and are therefore not absolutely identical to the original active ingredient. Production takes place in living cells, which is a highly sensitive process and leads to natural variability. Although the biosimilars do not differ in clinical effect from the original, the biologics, the former nevertheless exhibit significant differences such as an altered glycosylation pattern. However, the amino acid sequence of the biosimilars is identical to their original.

Leinco has a comprehensive range of recombinant biosimilars that meet stringent product qualifications and have undergone IMPAT testing. Therapeutic-grade antibodies are widely used in cancer and autoimmune diseases, but they are very expensive, difficult to obtain and available only in large quantities, making them difficult to fund for studies. In contrast, Leinco's recombinant biosimilar antibodies have great advantages for research purposes. With recombinant technology, variable sequence regions of the biologics can be generated, resulting in the same specificities of the original.

Leinco thus offers a fast and cost-effective alternative. The biosimilar antibodies are produced in animal-free facilities, stored in sterile PBS buffers and are free of additives and preservatives.

Available high purity research grade biosimilar antibodies with the same specifications as the following therapeutic antibodies are: Trastuzumab, Efalizumab, Mogamulizumab, Rituximab, Tabalumab, Nivolumab, Natalizumab, Alemtuzumab, Ipilimumab, Drozitumab, Cetuximab, Briakinumab, Basiliximab, Sarilumab, Oxelumab, Adalimumab and Bevacizumab. All antibodies are available with Fc-Active or Fc-Muted™ effector functions.

Note: All names for therapeutic monoclonal antibodies end with the suffix -mab. Pure mouse antibodies end in -omab. For chimeric antibodies (-ximab), only the variable portion of the immunoglobulin is still mouse protein; for humanized antibodies (-zumab), the mouse protein portion is reduced to the complementarity determining regions (CDR); human antibodies (-umab) have only human protein sequences.

Table 6 - Product selection for biosimilar antibodies

Biosimilar Antibodies Therapeutisc use SKU
Anti-Human TNF alpha (Adalimumab) To reduce inflammation of the joints, skin, spine, intestines and eyes.* Active: LT100
Muted: LT105
Anti-Human CD52 (Alemtuzumab) For the treatment of chronic lymphocytic leukemia (CLL) and multiple sclerosis.* Active: LT200
Muted: LT205
Anti-Human IL-2R alpha (Basiliximab) To prevent rejection in organ transplants, especially kidney transplants.* Active: LT300
Muted: LT305
Anti-Human VEGF (Bevacizumab) Used to treat colon cancer, lung cancer, glioblastoma, renal cell carcinoma and some eye diseases.* Active: LT400
Muted: LT405
Anti-Human IL 12/23 (Briakinumab) For the treatment of rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis.* Active: LT500
Muted: LT505
Anti-Human EGFR (Cetuximab) Used to treat metastatic colon cancer and head and neck cancer.** Active: LT600
Muted: LT605
Anti-Human DR5 (Drozitumab) For the treatment of various types of cancer.* Active: LT700
Muted: LT705

*These products are for research use only and should not be used for therapeutic purposes.

Recombinant Proteins, Growth Factors & Cytokines

Leinco offers biologically active recombinant proteins from a variety of host cells for research. In order to achieve the highest level of biological activity, mammalian expression systems are often used, using Chinese hamster ovary (CHO) or human embryonic kidney (HEK) cells as host cells. Thus, Leinco can provide you with the ability to use recombinant growth factors, cytokines, and receptors that are most similar to the native structure, including post-translational modifications such as glycosylation. The recombinant antibodies, proteins and other recombinant products are manufactured in an animal-free, cGMP-compliant facility under Leinco's ISO quality system.

Table 7- Product selection for recombinant proteins

Name SKU
Recombinant Human ALK-1 A343
Recombinant Human Activin RIIB A340
Recombinant Human ApoE4 A219
Recombinant Human BCAM B534
Recombinant Human Cathepsin L C1363

Discover Leinco's SARS-CoV-2 Reagents

Leinco is at your service with antibodies, recombinant products and assays for your SARS-CoV-2 research questions. Explore Leinco's wide range of products to help them develop diagnostic tests, therapeutics or vaccines.

Table 8- Product selection for SARS-CoV-2 reagents

Category Name Application Clone SKU
SARS-CoV-2 COVID-19 Trace™ IgG ELISA COVID-19 Trace™ IgG MICRO-ELISA Kit ELISA Det - S1500-90 Tests
SARS-CoV-2 Antibodies Anti-SARS-CoV-2 Nucleocapsid (N) ELISA, IHC, WB 1C7C7 LT7000
SARS-CoV-2 Recombinant Proteins Recombinant SARS-CoV-2, RBD Protein (Beta, B1.351, South Africa Variant) ELISA - S151
Cytokine Storm Recombinant Human IL-10 - - I-193
Support Tools and Additional Reagents Anti-Human Cathepsin L ELISA Cap, IHC FFPE, IP, WB - C1391

Antibodies for flow cytometry wanted?

Leinco offers antibodies specifically designed for flow cytometry that can be labeled with a variety of fluorescent dyes. This allows you to perform multicolor analysis of cellular subsets, through specific binding to intracellular antigens or cell surface receptors

The following reporter molecules are available for you: Biotin, FITC, R-PE, APC and PerCP conjugated monoclonal antibodies for immunophenotyping of cell populations, as well as various DyLights®. In addition, products of interest such as the Annexin V - FITC (part number A432) apoptosis detection kit, lysing buffer (part number R1364) and staining solutions (part number F1175) are available.

Table 9- Product Selection for Flow Cytometry by Clone

Category Name Clone
Human FC Antibodies Anti-Human CD14 (Monocytes) UCHM-1
Human FC Antibodies Anti-Human CD13 (Myeloid Cells) 22A5
Mouse FC Antibodies Anti-Mouse CD11c N418
Mouse TCR Antibodies Anti-Mouse β (TCR) H57-597
Human MHC Antibodies Anti-Human HLA-A, B, C Monomorphic W6/32
Human Immunoglobulins Anti-Human IgE 121

We are very pleased to offer you the wide range of products from Leinco Technologies.

Search for products by Leinco Technologies

Leinco Technologies products by Product Category

Any other questions?

If you have any questions, we are always at your disposal.
If you have not found a product, just send us a request and we'll take care of the rest.
Feel free to use our online services for your request.

 

Our Online-Service

 

Product Request
Recall Request
Easy Ordering
Bulk Request